ZOCITH™ 200

ZOCITH™ 200 contains azithromycin at double the concentration of the 100mg/5mL formulation, delivering 200mg per 5mL. It shares the identical mechanism of action as ZOCITH™ 100 — inhibition of bacterial protein synthesis via reversible binding to the 50S ribosomal subunit, blocking translocation and halting polypeptide elongation.

The 200mg/5mL concentration is designed for older and heavier paediatric patients (approximately 15–40 kg) where the 100mg/5mL suspension would require impractically large volumes to achieve the 10mg/kg/day weight-based dose. At this higher concentration, the target dose is achieved with a smaller, more manageable volume — improving dosing accuracy and parental convenience. The unique pharmacokinetics of azithromycin — 68-hour tissue half-life, 10–100x intracellular concentration versus plasma — apply equally at both concentrations, ensuring reliable tissue-level bacteriostatic and bactericidal activity at the sites of infection.

Same indications as ZOCITH™ 100 — community-acquired pneumonia (typical and atypical), acute otitis media (penicillin-allergy alternative or treatment failure), pharyngitis and tonsillitis, acute sinusitis, and skin infections — but specifically formulated for children in the 15–40 kg weight range (approximately 4–12 years) where the higher-concentration suspension allows practical weight-based dosing with smaller administration volumes.

Dosage and administration should be as prescribed by a qualified doctor or medical professional. Do not self-medicate. Always follow your physician's instructions regarding dose, frequency and duration of treatment.